Dr. Merve Keskinkilic | Medical Oncology | Best Researcher Award
Medical Oncologist, Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital Turkey
Merve Keskinkılıç is a dedicated Medical Oncologist at Burdur State Hospital with a strong academic background in Internal Medicine and Medical Oncology. She earned her M.D. from Dokuz Eylul University Faculty of Medicine and completed her Medical Oncology Fellowship at the same institution. Dr. Keskinkılıç has extensive clinical experience, having served as a Research Fellow at Emory University, USA. Fluent in English (C1 Advanced) and proficient in German (Elementary), she actively participates in international oncology research. Her expertise includes clinical trials, cancer treatment strategies, and translational oncology research, contributing significantly to advancements in the field.
Publication Profile
🎓 Education
Dr. Keskinkılıç completed her high school education at Balıkesir Science High School (2004-2008) before pursuing medicine at Dokuz Eylul University (2008-2014). She participated in an Oncology Exchange Program at Mansoura University, Egypt (2010). She later obtained an Associate Degree in Healthcare Management from Anadolu University (2014-2017). Her residency in Internal Medicine was completed at Celal Bayar University (2015-2016) and Dokuz Eylul University (2016-2019). She pursued a Medical Oncology Fellowship at Dokuz Eylul University (2019-2024) and is currently undertaking a PhD in Basic Oncology at Dokuz Eylul University Oncology Institute (since 2022). She also worked as a Research Fellow at Emory University, USA (2023).
💼 Experience
Dr. Keskinkılıç began her career as a General Practitioner at Balıkesir Susurluk State Hospital (2014-2015) before becoming a Research Assistant in Internal Medicine at Celal Bayar University (2015-2016) and later at Dokuz Eylul University (2016-2019). She served as a Specialist Doctor at Bitlis Mutki State Hospital (2019) and as a Fellow in Medical Oncology at Dokuz Eylul University (2019-2024). Currently, she is a Medical Oncologist at Burdur Public Hospital (2024-2025) and will join Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital in 2025.
🏆 Awards & Honors
Dr. Keskinkılıç holds several prestigious certifications, including the Turkish Board of Internal Medicine Certificate (2018), Experimental Animal Use Certificate (2019), Oncology Clinical Research Training Certificate (2020), and ESMO Board of Examination Certificate (2023). She has also completed Good Clinical Practices (ICU) and Clinical Research Training and has received certifications in Research Ethics and Clinical Trials. Her contributions to oncology research and education have been recognized through multiple national and international accolades.
🔬 Research Focus
Dr. Keskinkılıç specializes in clinical oncology research, focusing on urothelial, bladder, gastric, prostate, and lung cancers. She is actively involved in multiple clinical trials, serving as a Sub-Investigator in research projects such as THOR (Urothelial Cancer), Niagara (Bladder Cancer), MK3475-859 (Gastric Cancer), Regeneron (Non-Small Cell Lung Cancer), and Radiant 20510 (Prostate Cancer). Her work emphasizes innovative treatment strategies, immunotherapy, and targeted cancer therapies, contributing to the development of advanced oncological treatments. Her internal medicine dissertation evaluated CMV DNA Antigenemia in Allogeneic Bone Marrow Transplant Patients.
Publication Top Notes
- Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
- Authors: C. Karacin, B. Oksuzoglu, A. Demirci, M. Keskinkılıç, et al.
- Journal: BMC Cancer, 2023
- Citations: 20
- Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
- Authors: S. Kahraman, E. Erul, M. Seyyar, O. Gumusay, et al.
- Journal: Future Oncology, 2023
- Citations: 13
- Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: a multicenter study
- Authors: H. Ç. Yıldırım, E. Mutlu, E. Chalabiyev, M. Özen, et al.
- Journal: The Breast, 2022
- Citations: 13
- The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor-positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and…
- Authors: E. C. Yildirim, E. Atag, E. Coban, et al.
- Journal: The Breast, 2023
- Citations: 12
- Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia
- Authors: H. C. Yildirim, C. Kapar, B. Koksal, et al.
- Journal: Journal of Chemotherapy, 2024
- Citations: 4
- The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index
- Authors: M. Keskinkilic, H. S. Semiz, G. Polat, et al.
- Journal: Future Oncology, 2023
- Citations: 4
- Antibody-Drug Conjugates in Triple Negative Breast Cancer
- Authors: M. Keskinkilic, R. Sacks
- Journal: Clinical Breast Cancer, 2024
- Citations: 3
- 194P Increased blood creatinine level due to CDK 4/6 inhibitor treatments: single center experience
- Authors: M. Keskinkılıç, H. S. Semiz, T. Yavuzsen, A. Karaoglu
- Journal: Annals of Oncology, 2022
- Citations: 3
- The prognostic nutritional index (PNI): A new biomarker for determining prognosis in metastatic castration-sensitive prostate carcinoma
- Authors: H. I. Ellez, M. Keskinkilic, et al.
- Journal: Journal of Clinical Medicine, 2023
- Citations: 11
- The role of immune checkpoint inhibition in triple-negative breast cancer
- Authors: K. Tarekegn, M. Keskinkilic, T. J. Kristoff, S. T. Evans, K. Kalinsky
- Journal: Expert Review of Anticancer Therapy, 2023
- Citations: 10
- The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer
- Authors: M. Hizal, B. Bilgin, N. Paksoy, et al.
- Journal: Journal of Cancer Research and Clinical Oncology, 2023
- Citations: 5
- CD47 (‘don’t eat me’ signal) expression levels and its relationship with clinicopathologic features in early‐stage prostate carcinoma
- Authors: H. S. Semiz, Ü. Küçük, E. Kısa, M. Keskinkılıç, et al.
- Journal: The Prostate, 2022
- Citations: 5
- A severe case of levothyroxine intoxication successfully treated in intensive care unit
- Authors: Y. Savran, T. Mengi, M. Keskinkilic
- Journal: Journal of Acute Disease, 2018
- Citations: 11
Education
Experience
Award and Honor
Research Focus